KR102217607B1 - A composition for improving memory and cognitive function, preventing and improving ischemia reperfusion injury including acorus gramineus soland extract - Google Patents
A composition for improving memory and cognitive function, preventing and improving ischemia reperfusion injury including acorus gramineus soland extract Download PDFInfo
- Publication number
- KR102217607B1 KR102217607B1 KR1020200065703A KR20200065703A KR102217607B1 KR 102217607 B1 KR102217607 B1 KR 102217607B1 KR 1020200065703 A KR1020200065703 A KR 1020200065703A KR 20200065703 A KR20200065703 A KR 20200065703A KR 102217607 B1 KR102217607 B1 KR 102217607B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- improving
- cognitive function
- reperfusion injury
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 136
- 239000000203 mixture Substances 0.000 title claims abstract description 75
- 230000003920 cognitive function Effects 0.000 title claims abstract description 29
- 230000006386 memory function Effects 0.000 title claims abstract description 27
- 206010063837 Reperfusion injury Diseases 0.000 title abstract description 39
- 230000003405 preventing effect Effects 0.000 title abstract description 21
- 244000001632 Acorus gramineus Species 0.000 title abstract 4
- 235000013073 Acorus gramineus Nutrition 0.000 title abstract 4
- 208000012947 ischemia reperfusion injury Diseases 0.000 title description 8
- 235000013305 food Nutrition 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 10
- 240000006079 Schisandra chinensis Species 0.000 claims description 7
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 7
- 235000020237 cranberry extract Nutrition 0.000 claims description 7
- 235000020737 peppermint extract Nutrition 0.000 claims description 7
- 241001444063 Aronia Species 0.000 claims description 5
- 235000005979 Citrus limon Nutrition 0.000 claims description 5
- 244000131522 Citrus pyriformis Species 0.000 claims description 5
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 5
- 240000009088 Fragaria x ananassa Species 0.000 claims description 5
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 5
- 235000010676 Ocimum basilicum Nutrition 0.000 claims description 5
- 240000007926 Ocimum gratissimum Species 0.000 claims description 5
- 229940064008 acai berry extract Drugs 0.000 claims description 5
- 229940055416 blueberry extract Drugs 0.000 claims description 5
- 235000019216 blueberry extract Nutrition 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 235000019219 chocolate Nutrition 0.000 claims description 5
- 229940065115 grapefruit extract Drugs 0.000 claims description 5
- 235000020723 lavender extract Nutrition 0.000 claims description 5
- 235000020729 noni extract Nutrition 0.000 claims description 5
- 229940117336 parsley extract Drugs 0.000 claims description 5
- 235000020752 sage extract Nutrition 0.000 claims description 5
- 150000001298 alcohols Chemical class 0.000 claims description 4
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 claims description 3
- 229940083980 lavender extract Drugs 0.000 claims description 3
- 229940105902 mint extract Drugs 0.000 claims description 3
- 229940112950 sage extract Drugs 0.000 claims description 3
- 235000008216 herbs Nutrition 0.000 claims description 2
- 240000003296 Petasites japonicus Species 0.000 claims 1
- 235000003823 Petasites japonicus Nutrition 0.000 claims 1
- 235000001436 butterbur Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 40
- 230000000302 ischemic effect Effects 0.000 abstract description 36
- 230000010410 reperfusion Effects 0.000 abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 208000023589 ischemic disease Diseases 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 4
- 229930014626 natural product Natural products 0.000 abstract description 4
- 208000028867 ischemia Diseases 0.000 description 28
- 230000006378 damage Effects 0.000 description 19
- 235000013376 functional food Nutrition 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 210000004556 brain Anatomy 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 230000036541 health Effects 0.000 description 12
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 11
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 11
- 210000000056 organ Anatomy 0.000 description 11
- 239000001301 oxygen Substances 0.000 description 11
- 229910052760 oxygen Inorganic materials 0.000 description 11
- 235000019629 palatability Nutrition 0.000 description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
- 230000030833 cell death Effects 0.000 description 10
- 230000036542 oxidative stress Effects 0.000 description 10
- 208000006011 Stroke Diseases 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 239000003642 reactive oxygen metabolite Substances 0.000 description 9
- 235000019640 taste Nutrition 0.000 description 9
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 8
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 210000004204 blood vessel Anatomy 0.000 description 7
- 230000003833 cell viability Effects 0.000 description 7
- 206010008118 cerebral infarction Diseases 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 108010057466 NF-kappa B Proteins 0.000 description 6
- 102000003945 NF-kappa B Human genes 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 201000006474 Brain Ischemia Diseases 0.000 description 5
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 5
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000036770 blood supply Effects 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 5
- 230000000451 tissue damage Effects 0.000 description 5
- 231100000827 tissue damage Toxicity 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 102100033639 Acetylcholinesterase Human genes 0.000 description 4
- 108010022752 Acetylcholinesterase Proteins 0.000 description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 208000032382 Ischaemic stroke Diseases 0.000 description 4
- 206010028851 Necrosis Diseases 0.000 description 4
- 210000005013 brain tissue Anatomy 0.000 description 4
- 235000019537 butterbur extract Nutrition 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010022680 Intestinal ischaemia Diseases 0.000 description 3
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 208000037906 ischaemic injury Diseases 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- -1 pH adjusters Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- AAXWBCKQYLBQKY-IRXDYDNUSA-N (2s)-2-[[(2s)-2-[(2-benzamidoacetyl)amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)C=1C=CC=CC=1)C1=CN=CN1 AAXWBCKQYLBQKY-IRXDYDNUSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 229920005439 Perspex® Polymers 0.000 description 2
- 241000208317 Petroselinum Species 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000005775 apoptotic pathway Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 108010016268 hippuryl-histidyl-leucine Proteins 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000006676 mitochondrial damage Effects 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 235000011197 perejil Nutrition 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960000103 thrombolytic agent Drugs 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- SMBBQHHYSLHDHF-UHFFFAOYSA-M 2-acetyloxyethyl(trimethyl)azanium;iodide Chemical compound [I-].CC(=O)OCC[N+](C)(C)C SMBBQHHYSLHDHF-UHFFFAOYSA-M 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- 208000025962 Crush injury Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 1
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000004535 Mesenteric Ischemia Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 238000010632 SOD assay Methods 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 201000002818 limb ischemia Diseases 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000010405 reoxidation reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 231100000152 severe skin burn Toxicity 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/882—Acoraceae (Calamus family), e.g. sweetflag or Acorus calamus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 석창포 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물에 관한 것이다. 보다 상세하게는 기억력 및 인지기능 개선 활성과 허혈 재관류 손상을 예방 또는 완화하여 허혈성 재관류 손상 등에 의한 질환을 예방 및 개선할 수 있는 조성물을 제공하기 위한 것이다.The present invention relates to a composition for improving memory and cognitive function, preventing and improving ischemia reperfusion injury, including seokchangpo extract. In more detail, it is intended to provide a composition capable of preventing and improving diseases caused by ischemic reperfusion injury by preventing or alleviating the activity of improving memory and cognitive function and ischemic reperfusion injury.
대표적인 허혈성 질환인 뇌경색과 심근경색은 고혈압, 고지혈증, 당뇨, 흡연 등에 의해 혈관이 좁아지는 동맥경화증에 빠진 상태에서 혈전 등에 의해 뇌에 혈액을 공급하는 뇌동맥 또는 심장에 혈액을 공급하는 관상동맥이 막혀 주위조직이 괴사됨으로써 발생한다.Cerebral infarction and myocardial infarction, which are typical ischemic diseases, are caused by clogging of the cerebral artery supplying blood to the brain or the coronary artery supplying blood to the heart in a state of atherosclerosis, where blood vessels are narrowed by high blood pressure, hyperlipidemia, diabetes, or smoking. It is caused by tissue necrosis.
특히, 뇌졸중은 크게 뇌 혈관이 협착되거나 혈전에 의해 막힘으로 인하여 혈액 공급이 차단되었을 때 일어나는 뇌 허혈과 두개 내의 출혈로 인한 뇌 출혈로 나눌 수 있다. 그 중에서 뇌 허혈은 혈액 공급 차단으로 인해 산소와 영양분의 결핍이 일어남으로써 신경세포에서 ATP 감소가 일어나고 부종이 발생하여 직접적인 세포의 손상 및 괴사를 유도한다. 이러한 부종은 뇌의 원활한 역할을 방해하고 조직의 괴사를 유도하여 광범위한 뇌 조직 손상을 유도하여 손상 부위에 따른 이차적인 행동 장애나 인지 장애 등을 유발하게 된다. 따라서 대부분의 뇌졸중 환자들은 혈전을 제거한 후에도 뇌 조직 손상에 따른 행동 장애를 가지게 되고, 이 또한 뇌졸중 치료 중 중요한 부분이라고 할 수 있다. 또한, 최근에는 사망원인 1위일 만큼 빈번히 발생하는 질환이다. 현재 뇌허혈에 대한 치료제는 FDA의 승인을 받은 t-PA (tissue plasminogen activator)가 있는데, 이것은 혈전 용해제로써 막혀 있는 혈전을 제거하고 빠르게 혈액을 다시 공급해 주는 처치인데, 처치가 발생 3시간 이내에 이루어 져야 하고, 출혈성 뇌 허혈의 가능성이 동시에 있을 경우는 사용할 수 없는 등의 한계가 있다.In particular, stroke can be divided into cerebral ischemia and cerebral hemorrhage due to intracranial hemorrhage, which occurs when blood supply is blocked due to stenosis or blockage of blood clots in the brain. Among them, cerebral ischemia causes deficiency of oxygen and nutrients due to the blockage of blood supply, resulting in a decrease in ATP and edema in nerve cells, leading to direct cell damage and necrosis. Such edema interferes with the smooth role of the brain and induces tissue necrosis, leading to extensive brain tissue damage, resulting in secondary behavioral disorders or cognitive disorders depending on the damaged area. Therefore, most stroke patients have behavioral disorders due to brain tissue damage even after the blood clot is removed, and this is also an important part of stroke treatment. In addition, it is a disease that occurs frequently as the number one cause of death in recent years. Currently, the treatment for cerebral ischemia is FDA-approved t-PA (tissue plasminogen activator), which is a thrombolytic agent that removes clots and quickly resupplies blood.The treatment must be done within 3 hours of occurrence. However, there are limitations such as not being able to use it when there is a possibility of hemorrhagic cerebral ischemia at the same time.
한편, 허혈(ischemia)이란 생리적 기능에 요구되는 산소 요구량보다 산소공급이 부족한 상태로 국소적 혈류의 감소를 말하고, 재관류(reperfusion)란 혈액이 다시 조직에 공급되는 것으로 허혈성 조직의 생존에 필수적이지만 허혈 동안 산화성 손상에 매우 민감한 경향이 있는 조직들의 재산화로 인해 조직의 손상이 더욱 가속화된다. 이를 허혈 재관류 손상(ischemia/reperfusion injury; IRI)이라 한다.On the other hand, ischemia refers to the reduction of local blood flow due to insufficient oxygen supply than the oxygen demand required for physiological functions, and reperfusion is the supply of blood back to the tissue, which is essential for the survival of ischemic tissue, but ischemia. Tissue damage is further accelerated due to the reoxidation of tissues that tend to be highly susceptible to oxidative damage. This is called ischemia/reperfusion injury (IRI).
허혈-재관류 손상은 병적 상태를 일으키는 것으로 잘 알려져 있다. 예견된 병적 상태 또는 예견되지 않은 병적 상태를 나타낼 수도 있다. 상술한 뇌졸증은 예견되지 않은 허혈-재관류 손상의 가장 일반적인 형태 중의 하나로서 상기 뇌졸증은 산업화된 국가들에서 사망 3번째 원인이고, 장기간 장애의 주요한 원인이다. 뇌졸증은 뇌 안에 그리고 뇌에 이르는 동맥에 영향을 주는 심장혈관의 질병의 일종이다. 뇌졸증은 그러한 동맥들이 클럿(clot)에 의해 막히고, 막힌 동맥으로 인해 대뇌 조직의 허혈이 생길 때 일어난다. 뇌의 직접적인 손상은 혈류의 방해에 의해 일어나고, 주로 생체 조직에 산화(oxygenation)의 결여 때문에, 결국 바뀌지 않으면 경색이 일어난다. 그러나 그런 손상이 바뀌면 (생리학적으로 또는 치료적으로), 그리고나서 허혈 조직의 재관류는 역설적으로 추가적인 간접적 손상을 일으킬 수 있다. 허혈이 오래 지속될 때, 산소결핍 단독으로부터 오는 "직접적인" 손상이 주요한 기전이다. 허혈의 짧은 지속을 위한, 간접 또는 재관류 매개된 손상은 최종 결과에 더 증가하게 중요해지고 있다.Ischemia-reperfusion injury is well known to cause pathological conditions. It may indicate a predicted or unforeseen pathological condition. Stroke described above is one of the most common forms of unforeseen ischemia-reperfusion injury, which is the third cause of death in industrialized countries and a leading cause of long-term disability. Stroke is a type of cardiovascular disease that affects the arteries in and to the brain. Stroke occurs when such arteries are clogged by a clot, and ischemia of cerebral tissue occurs due to the blocked artery. Direct damage to the brain is caused by obstruction of blood flow, mainly due to the lack of oxygenation in living tissues, eventually causing infarction if not changed. However, if such damage is changed (physiologically or therapeutically), then reperfusion of the ischemic tissue can paradoxically cause additional indirect damage. When ischemia is prolonged, "direct" damage from oxygen starvation alone is a major mechanism. For the short duration of ischemia, indirect or reperfusion mediated injury is becoming increasingly important to the end result.
그러나, 현재까지 개발된 허혈에 대한 치료방법으로는 빠른시간 내에 허혈이 발생한 콩팥의 막힌 혈관을 혈전용해제 등으로 뚫어 혈관을 재관류시키는 것이 최선이나, 재관류 시키더라도 조직들이 괴사된 조직에서의 치료효과는 기대할 수 없고, 재관류에 의한 추가적인 손상 또한 피할 수 없을 뿐만 아니라 콩팥 이식시, 이식된 콩팥의 회복 지연, 급성 거부반응의 증가 및 장기적인 이식 콩팥의 생존율을 감소시키기까지 한다.However, as a treatment method for ischemia developed so far, it is best to reperfusion the blood vessels by piercing the clogged blood vessels of the kidney where ischemia occurred in a short time with a thrombolytic agent, etc., but even if reperfusion is performed, the therapeutic effect in the necrotic tissues It is unpredictable, and additional damage due to reperfusion is also inevitable, as well as delaying recovery of the transplanted kidney, increasing acute rejection, and reducing the survival rate of long-term transplanted kidneys during kidney transplantation.
즉 다양한 외과적 수술에서 발생할 수 있는 허혈-재관류 손상에 있어서, 임상에서 적용될 수 있는 치료 제가 아직까지 없는 실정이어서 여러 임상적 상황에서 나타날 수 있는 신장 등의 장기에 대한 손상을 효과적으로 억제할 수 있는 의약품 개발이 절실하다. 이에 뇌, 심장혈관, 간에서의 허혈로 인한 물질과 기전을 밝히는 연구가 지속되고 있으나, 그 성과는 부족한 실정이다.In other words, for ischemia-reperfusion injury that can occur in various surgical operations, there is no clinically applicable treatment agent yet, so drugs that can effectively suppress damage to organs such as kidneys that may appear in various clinical situations. Development is urgent. Accordingly, researches to reveal substances and mechanisms caused by ischemia in the brain, cardiovascular system, and liver are continuing, but the results are insufficient.
따라서 상기 허혈 재관류 손상을 보다 효율적으로 예방 및 개선할 수 있도록 하는 물질에 대한 개발이 요구되고 있다.Therefore, there is a need for development of a material that can more efficiently prevent and improve the ischemic reperfusion injury.
본 발명의 목적은 천연물을 기반으로 한 기억력 및 인지기능 개선효과를 가지는 석창포 추출물을 포함하는 조성물을 제공하기 위한 것이다.It is an object of the present invention to provide a composition comprising a seokchangpo extract having an effect of improving memory and cognitive function based on natural products.
본 발명의 목적은 허혈성 재관류 손상의 예방 및 개선 효과를 가지는 석창포 추출물을 포함하는 조성물을 제공하기 위한 것이다.It is an object of the present invention to provide a composition comprising a seokchangpo extract having an effect of preventing and improving ischemic reperfusion injury.
본 발명에 따른 석창포 추출물을 포함하는 조성물은 천연 추출물로서, 세포독성 등의 부작용의 문제가 없어 장기간 사용하면서, 기억력 및 인지기능 개선, 허혈성 재관류 손상의 예방 및 개선 효과를 낼 수 있도록 하기 위한 것이다.The composition comprising the seokchangpo extract according to the present invention is a natural extract and is intended to improve memory and cognitive function, prevent and improve ischemic reperfusion injury while using it for a long time because there is no problem of side effects such as cytotoxicity.
본 발명의 목적은 석창포 추출물을 포함하는 기억력 및 인지기능 개선, 허혈성 재관류 손상의 예방 및 개선용 조성물을 식품, 건강기능식품 등의 제형으로 제공할 수 있게 하기 위한 것이다.An object of the present invention is to be able to provide a composition for improving memory and cognitive function including seokchangpo extract and preventing and improving ischemic reperfusion injury in a formulation such as food and health functional food.
상기 목적을 달성하기 위하여, 본 발명의 일 실시예에 따른 기억력 및 인지기능 개선용 조성물은 석창포 추출물을 포함하는 것일 수 있다.In order to achieve the above object, the composition for improving memory and cognitive function according to an embodiment of the present invention may include a seokchangpo extract.
상기 기억력 및 인지기능 개선용 조성물에 있어서, 상기 추출물은 물, 탄소수 1 내지 10의 알코올 및 이들의 혼합물로 이루어진 군에서 선택된 어느 하나를 용매로 추출된 것일 수 있다.In the composition for improving memory and cognitive function, the extract may be one selected from the group consisting of water, an alcohol having 1 to 10 carbon atoms, and a mixture thereof, extracted with a solvent.
본 발명의 다른 일 실시예에 따른 허혈성 재관류 손상의 예방 및 개선용 조성물은 석창포 추출물을 포함하는 것일 수 있다.The composition for preventing and improving ischemic reperfusion injury according to another embodiment of the present invention may include seokchangpo extract.
상기 허혈성 재관류 손상의 예방 및 개선용 조성물에 있어서, 상기 추출물은 물, 탄소수 1 내지 10의 알코올 및 이들의 혼합물로 이루어진 군에서 선택된 어느 하나를 용매로 추출된 것일 수 있다.In the composition for preventing and improving ischemic reperfusion injury, the extract may be extracted with a solvent of any one selected from the group consisting of water, alcohols having 1 to 10 carbon atoms, and mixtures thereof.
본 발명에 또 다른 실시예에 따른 기억력 및 인지기능개선용 식품은 상기 조성물을 포함하고, 오미자 추출물, 딸기 추출물, 아사이베리 추출물, 아로니아 추출물, 블루베리 추출물, 크랜베리 추출물, 자몽 추출물, 오렌지 추출물, 레몬 추출물, 초코민트 추출물, 바질 추출물, 페퍼민트 추출물, 세이지 추출물, 라벤더 추출물, 파슬리 추출물, 곰피 추출물, 방풍나물 추출물, 머위 추출물, 달래 추출물, 차즈기 추출물, 노니 추출물 및 이들의 혼합물로 이루어진 군에서 선택된 어느 하나를 더 포함하는 것일 수 있다.The food for improving memory and cognitive function according to another embodiment of the present invention includes the composition, and includes the composition, Schisandra chinensis extract, strawberry extract, acai berry extract, aronia extract, blueberry extract, cranberry extract, grapefruit extract, orange extract, Selected from the group consisting of lemon extract, chocolate mint extract, basil extract, peppermint extract, sage extract, lavender extract, parsley extract, gomskin extract, windworm extract, butterbur extract, soothing extract, chazum extract, noni extract, and mixtures thereof It may further include any one.
본 발명에 또 다른 실시예에 따른 허혈성 재관류 손상의 예방 및 개선용 식품은 상기 조성물을 포함하고, 오미자 추출물, 딸기 추출물, 아사이베리 추출물, 아로니아 추출물, 블루베리 추출물, 크랜베리 추출물, 자몽 추출물, 오렌지 추출물, 레몬 추출물, 초코민트 추출물, 바질 추출물, 페퍼민트 추출물, 세이지 추출물, 라벤더 추출물, 파슬리 추출물, 곰피 추출물, 방풍나물 추출물, 머위 추출물, 달래 추출물, 차즈기 추출물, 노니 추출물 및 이들의 혼합물로 이루어진 군에서 선택된 어느 하나를 더 포함하는 것일 수 있다.Food for the prevention and improvement of ischemic reperfusion injury according to another embodiment of the present invention comprises the composition, and Schisandra chinensis extract, strawberry extract, acai berry extract, aronia extract, blueberry extract, cranberry extract, grapefruit extract, orange Group consisting of extracts, lemon extracts, chocolate mint extracts, basil extracts, peppermint extracts, sage extracts, lavender extracts, parsley extracts, gompi extracts, windworm extracts, butterbur extract, soothing extracts, chazugi extract, noni extract, and mixtures thereof It may be to further include any one selected from.
이하, 본 발명을 더욱 상세하게 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명의 일 실시예에 따른 기억력 및 인지기능 개선용 조성물은 석창포 추출물을 포함하는 것일 수 있다.The composition for improving memory and cognitive function according to an embodiment of the present invention may include seokchangpo extract.
상기 석창포(石菖蒲)는 사철 푸른 잎을 가진 여러해살이풀이다. 뿌리줄기는 굵고 딱딱하며 많은 마디가 있으며 잔뿌리를 내어 바위틈과 같은 자리에 붙어산다. 잎은 뿌리줄기로부터 밑동이 서로 겹친 상태로 자라난다. 좁은 줄 꼴로 질기며 윤기가 난다. 잎 끝은 칼처럼 뾰족하고 가장자리는 밋밋하며 항상 좋은 향기를 풍긴다. 꽃은 잎과 같은 생김새를 가진 꽃대의 중간부에 둥근 막대기 모양으로 뭉쳐 핀다. 꽃이 뭉친 막대기의 길이는 5cm 안팎이고 빛깔은 노란빛을 띤 푸른색이다.The Seokchangpo (石菖蒲) is a perennial plant with green leaves in all seasons. The rhizome is thick and hard, has many nodes, has fine roots, and lives in a place like a rock. Leaves grow from the rootstock with the roots overlapping each other. It is tough and shiny in a narrow line. The tip of the leaf is sharp like a knife, the edge is flat, and it always smells good. Flowers are clustered in a round bar shape in the middle part of the flower stalk, which has a leaf-like shape. The length of the stick with flowers is around 5cm and the color is yellowish blue.
본 명세서에서 사용되는 용어 "추출물"은 상술한 바와 같이 당업계에서 조추출물(crude extract)로 통용되는 의미를 갖지만, 광의적으로는 추출물을 추가적으로 분획(fractionation)한 분획물도 포함한다. 즉, 석창포 추출물은 상술한 추출용매를 이용하여 수득한 것뿐만 아니라, 여기에 정제과정을 추가적으로 적용하여 얻은 것도 포함한다. 예컨대, 상기 추출물을 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 통과시켜 얻은 분획, 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등, 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 분획도 본 발명의 석창포 추출물에 포함되는 것이다.As used herein, the term "extract" has a meaning commonly used as a crude extract in the art as described above, but broadly includes a fraction obtained by further fractionating the extract. That is, the seokchangpo extract includes not only those obtained using the above-described extraction solvent, but also those obtained by additionally applying a purification process thereto. For example, fractions obtained by passing the extract through an ultrafiltration membrane having a certain molecular weight cut-off value, separation by various chromatography (made for separation according to size, charge, hydrophobicity or affinity), etc. Fractions obtained through the purification method are also included in the seokchangpo extract of the present invention.
상기 석창포 추출물은 기억력 및 인지기능을 개선하고 허혈성 질환을 예방 또는 개선하는 효과를 나타낼 수 있다.The Seokchangpo extract may exhibit an effect of improving memory and cognitive functions and preventing or improving ischemic diseases.
바람직하게 상기 허혈성 질환은 뇌졸중 또는 뇌경색인 것일 수 있다.Preferably, the ischemic disease may be a stroke or a cerebral infarction.
바람직하게 상기 기억력 및 인지기능 개선용 조성물은 원지 추출물, 곰피 추출물, 방풍나무 추출물 및 차즈기 추출물을 포함하는 것일 수 있다. 상기 범위에 의하는 경우 상호작용에 의한 상승효과로 기억력 및 인지기능 개선 활성이 높아질 수 있다.Preferably, the composition for improving memory and cognitive function may include a raw paper extract, a gompi extract, a windbreak tree extract, and a chazugi extract. In the case of the above range, the activity of improving memory and cognitive function may be increased due to a synergistic effect due to interaction.
더 바람직하게 상기 기억력 및 인지기능 개선용 조성물은 상기 석창포 추출물 100 중량부에 대하여 곰피 추출물 1 내지 5 중량부, 방풍나물 10 내지 20 중량부 및 차즈기 추출물 1 내 5 중량부를 더 포함하는 것일 수 있다. 상기 범위에 의하는 경우 기억력 및 인지기능개선 활성이 우수할 뿐만 아니라, 식품조성물로 제공하는 경우 맛과 향미가 개선될 수 있는 제형으로 제공될 수 있다. 한편, 원지 추출물을 함유하는 경우 기억력 및 인지기능 개선활성은 우수하나 식품조성물로 제공하는 경우 후술하는 다른 천연물을 배합하여도 원지의 기호성 낮은 향과 맛을 억제할 수가 없어 기호성 있는 식품 조성물로 제공할 수가 없다는 문제가 있다.More preferably, the composition for improving memory and cognitive function may further include 1 to 5 parts by weight of Gompi extract, 10 to 20 parts by weight of windbreak sprouts and 5 parts by weight in Chazugi extract 1 based on 100 parts by weight of the Seokchangpo extract. . In the case of the above range, not only has excellent memory and cognitive function improvement activity, but also can be provided in a formulation capable of improving taste and flavor when provided as a food composition. On the other hand, if it contains raw paper extract, it has excellent memory and cognitive function improvement activity, but if it is provided as a food composition, it is not possible to suppress the low palatability of aroma and taste of the original paper even if other natural products described below are mixed, so that it can be provided as a palatable food composition. There is a problem that you cannot.
상기 기억력 및 인지기능 개선용 조성물에 있어서, 상기 추출물은 물, 탄소수 1 내지 10의 알코올 및 이들의 혼합물로 이루어진 군에서 선택된 어느 하나를 용매로 추출된 것일 수 있다.In the composition for improving memory and cognitive function, the extract may be one selected from the group consisting of water, an alcohol having 1 to 10 carbon atoms, and a mixture thereof, extracted with a solvent.
바람직하게 상기 용매는 물일 수 있다. 물을 용매로 석창포 추출물을 제조하는 경우 유효물질 수득에 유리할 수 있다.Preferably, the solvent may be water. When preparing seokchangpo extract using water as a solvent, it may be advantageous to obtain an active substance.
본 발명의 다른 일 실시예에 따른 허혈성 재관류 손상의 예방 및 개선용 조성물은 석창포 추출물을 포함하는 것일 수 있다.The composition for preventing and improving ischemic reperfusion injury according to another embodiment of the present invention may include seokchangpo extract.
혈관 막힘과 좁아짐과 같은 허혈(ischemia)에 의한 조직 손상을 억제하기 위해 신속한 재관류(reperfusion)는 필수적이다. 그러나 혈액이 재관류 되는 과정에서 혈관내피세포 기능 저하와 같은 조직손상이 가중되는 추가적인 손상이 동반된다. 이것을 ‘허혈 재관류 손상(ischemia reperfusion injury; IRI)라 한다. 특히 조직이나 장기에 허혈이 발생하면 손상을 피할 수 없고, 이것은 재관류가 이루어지는 시간에 따라 그 범위나 손상 정도가 결정된다. 허혈 시간이 길어지면 비가역적인 손상이 발생하고 재관류가 이루어져도 재관류에 의해 심각한 손상을 받을 수 있다.Rapid reperfusion is essential to inhibit tissue damage caused by ischemia, such as blood vessel blockage and narrowing. However, in the process of blood reperfusion, additional damage is accompanied by increased tissue damage such as decreased vascular endothelial cell function. This is called'ischemia reperfusion injury (IRI). In particular, when ischemia occurs in tissues or organs, damage cannot be avoided, and the extent or degree of damage is determined depending on the time at which reperfusion is performed. If the ischemia time is prolonged, irreversible damage may occur, and even if reperfusion is performed, serious damage may be caused by reperfusion.
본 발명에서 "허혈성 손상"은 심장, 뇌, 신장 등 혈류공급을 필요로 하는 장기에서 혈액순환이 차단되면서 산소전달이 감소되어 발생하는 손상을 의미하며, 조직의 기능 손상 및 세포사를 초래할 수 있는 치명적 손상을 포함한다. 허혈성 손상을 일으킬 수 있는 원인으로는 혈관 질병, 관상동맥 혈전증, 뇌혈관 혈전증, 동맥류 파열, 전신 출혈, 압궤 손상, 패혈증, 심각한 피부 화상, 혈관 폐색성 수술 방법(예, 흉복 동맥류 수술 과정에서의 척수허혈), 심폐 우회로 방법, 장기 이식, 심폐 허탈(급성 심장사) 및 질식 등이 있으나 이에 제한되지 않는다.In the present invention, "ischemic injury" refers to damage that occurs due to reduced oxygen delivery while blocking blood circulation in organs that require blood flow such as the heart, brain, kidney, etc., which can lead to tissue function damage and cell death. Includes damage. Possible causes of ischemic injury include vascular disease, coronary artery thrombosis, cerebrovascular thrombosis, aneurysm rupture, systemic bleeding, crush injury, sepsis, severe skin burns, vascular occlusive surgical methods (e.g., spinal cord during thoracic aneurysm surgery). Ischemia), cardiopulmonary bypass method, organ transplantation, cardiopulmonary collapse (acute heart death), and asphyxiation, but are not limited thereto.
본 발명에서 "허혈성 손상"은 통상적으로 발생할 수 있는 허혈성 손상 외에 장기 이식 등으로 발생할 수 있는 허혈 재관류 손상을 포함한다.In the present invention, "ischemic injury" includes ischemic reperfusion injury that may occur due to organ transplantation in addition to ischemic damage that may normally occur.
본 발명에서 "허혈성 재관류 손상"은 심근 허혈, 뇌혈관 허혈, 신장 허혈, 간 허혈, 허혈 재관류 심근병증, 피부 허혈, 장관 허혈, 장 허혈, 위 허혈, 폐 허혈, 췌장 허혈, 골격근 허혈, 복근 허혈, 사지 허혈, 허혈 재관류 결장염, 장간막 허혈 및 무증후성 허혈로 이루어진 군으로부터 선택된 1종 이상의 허혈에 의해 생길 수 있으며, 이에 제한되는 것은 아니다.In the present invention, "ischemic reperfusion injury" refers to myocardial ischemia, cerebrovascular ischemia, kidney ischemia, liver ischemia, ischemia reperfusion cardiomyopathy, skin ischemia, intestinal ischemia, intestinal ischemia, gastric ischemia, pulmonary ischemia, pancreatic ischemia, skeletal muscle ischemia, abdominal muscle ischemia. , Limb ischemia, ischemia reperfusion colitis, mesenteric ischemia, and asymptomatic ischemia may be caused by one or more types of ischemia selected from the group consisting of, but is not limited thereto.
상기 허혈성 재관류 손상은 외상, 예컨대 급성 심근경색 후 혈류의 복구와 같은 자연적 사건 또는 혈액 공급 감소를 겪었던 조직 또는 기관에서 혈류의 복구, 또는 재관류 수술, 예컨대 혈액 공급 감소를 겪었던 조직 또는 기관에서 혈류를 복구시키는 하나 이상의 외과적 시술, 다른 치료적 개입(therapeutic intervention) 또는 장기 이식 수술과정에 의해 발생할 수 있다. 상기 외과적 시술에는 예를 들어 관상동맥 우회로 조성술, 관상 동맥 형성술, 기관 이식 수술 등이 포함된다.The ischemic reperfusion injury is a natural event, such as restoration of blood flow after an acute myocardial infarction, or restoration of blood flow in a tissue or organ that has undergone a decrease in blood supply, or restoration of blood flow in a tissue or organ that has undergone reperfusion surgery, such as a decrease in blood supply. It may be caused by one or more surgical procedures, other therapeutic interventions, or organ transplant procedures. The surgical procedure includes, for example, coronary artery bypass grafting, coronary artery formation, and organ transplantation.
예를 들어, 급성 심근경색은 심장의 혈관 중 하나가 폐쇄되면서 산소 및 영양공급이 이루어 지지 않아 심장 근육이 사멸, 괴사 되는 현상을 지칭하는데, 이 경우 보통 병원을 찾아와 1시간 이내에 혈관을 재관류 시켜주면 10% 이내로 사망률을 낮출 수가 있다. 하지만 10% 내외에 환자는 막혔던 혈관이 재관류 되면서 급격한 산소 공급으로 인해 심근세포가 손상을 받게 되는데 이를 재관류 손상이라 하고 이로 인하여 10% 내외에 환자가 시술 후 30일 내에 사망을 하고, 살아남은 환자 중에 30% 정도는 심부전 등의 증상을 얻게 된다.For example, acute myocardial infarction refers to the death and necrosis of the heart muscle as one of the blood vessels of the heart is closed and oxygen and nutrients are not provided.In this case, if you visit a hospital and reperfusion the blood vessel within 1 hour It can lower the mortality rate to within 10%. However, around 10% of patients suffer damage to cardiomyocytes due to rapid oxygen supply as the blocked blood vessels are reperfused. This is called reperfusion injury. Due to this, around 10% of patients die within 30 days of the procedure, and 30 of the surviving patients. About% will get symptoms such as heart failure.
상기 뇌혈관 질환은 뇌졸중, 뇌경색, 뇌혈전증, 뇌색전증 등을 포함하나, 이에 제한되는 것은 아니다. 상기 심혈관 질환은 심근경색, 협심증 등을 포함하나 이에 제한되는 것은 아니다.The cerebrovascular disease includes, but is not limited to, stroke, cerebral infarction, cerebral thrombosis, and cerebral embolism. The cardiovascular disease includes, but is not limited to, myocardial infarction and angina.
상기 석창포 추출물은 미토콘드라아 의존성 아포토시스 경로를 억제하여 허혈 재관류 손상을 예방 또는 완화하는 효과를 나타낼 수 있다. 이에 따라 허혈 재관류 손상에 따른 질병을 예방 및 개선할 수 있다.The seokchangpo extract may exhibit an effect of preventing or alleviating ischemic reperfusion injury by inhibiting a mitochondrial dependent apoptosis pathway. Accordingly, it is possible to prevent and improve diseases caused by ischemic reperfusion injury.
바람직하게 상기 허혈성 재관류 손상의 예방 및 개선용 조성물은 원지 추출물, 곰피 추출물, 방풍나무 추출물 및 차즈기 추출물을 포함하는 것일 수 있다. 상기 범위에 의하는 경우 상호작용에 의한 상승효과로 미토콘드리아 및 세포사멸을 방지하여 허혈 재관류 손상을 예방 및 개선하는 효과를 높일 수 있다.Preferably, the composition for preventing and improving ischemic reperfusion injury may include a raw paper extract, a gompi extract, a perspex extract, and a chazugi extract. In the case of the above range, it is possible to increase the effect of preventing and improving ischemic reperfusion injury by preventing mitochondria and cell death by synergistic effect due to interaction.
더 바람직하게 상기 허혈성 재관류 손상의 예방 및 개선용 조성물은 상기 석창포 추출물 100 중량부에 대하여 곰피 추출물 1 내지 5 중량부, 방풍나물 10 내지 20 중량부 및 차즈기 추출물 1 내 5 중량부를 더 포함하는 것일 수 있다. 상기 범위에 의하는 경우 항산화 활성 및 미토콘드리아 손상 또는 세포 사멸을 억제하는 효과로서 허혈 재관류 손상을 예방 및 개선하는 효과가 보다 향상될 수 있다. 이에 따라 보다 적은 함량으로 높은 활성을 나타내게 할 수 있다.More preferably, the composition for the prevention and improvement of ischemic reperfusion injury is to further include 1 to 5 parts by weight of Gompi extract, 10 to 20 parts by weight of windbreak herbs and 5 parts by weight of Chazumin extract 1 based on 100 parts by weight of the Seokchangpo extract I can. In the case of the above range, the effect of preventing and improving ischemic reperfusion injury as an effect of inhibiting antioxidant activity and mitochondrial damage or cell death may be more improved. Accordingly, it is possible to exhibit high activity with a smaller content.
상기 허혈성 재관류 손상의 예방 및 개선용 조성물에 있어서, 상기 추출물은 물, 탄소수 1 내지 10의 알코올 및 이들의 혼합물로 이루어진 군에서 선택된 어느 하나를 용매로 추출된 것일 수 있다.In the composition for preventing and improving ischemic reperfusion injury, the extract may be extracted with a solvent of any one selected from the group consisting of water, alcohols having 1 to 10 carbon atoms, and mixtures thereof.
바람직하게 상기 용매는 물인 것일 수 있다. 물을 용매로 추출하는 경우 유효물질 수득에 유리할 수 있다.Preferably, the solvent may be water. When water is extracted with a solvent, it may be advantageous to obtain an active substance.
본 발명에 또 다른 실시예에 따른 기억력 및 인지기능 개선용 식품은 상기 조성물을 포함하고, 오미자 추출물, 딸기 추출물, 아사이베리 추출물, 아로니아 추출물, 블루베리 추출물, 크랜베리 추출물, 자몽 추출물, 오렌지 추출물, 레몬 추출물, 초코민트 추출물, 바질 추출물, 페퍼민트 추출물, 세이지 추출물, 라벤더 추출물, 파슬리 추출물, 곰피 추출물, 방풍나물 추출물, 머위 추출물, 달래 추출물, 차즈기 추출물, 노니 추출물 및 이들의 혼합물로 이루어진 군에서 어느 하나를 더 포함하는 것일 수 있다.The food for improving memory and cognitive function according to another embodiment of the present invention includes the composition, and includes the composition, Schisandra chinensis extract, strawberry extract, acai berry extract, aronia extract, blueberry extract, cranberry extract, grapefruit extract, orange extract, Any from the group consisting of lemon extract, chocolate mint extract, basil extract, peppermint extract, sage extract, lavender extract, parsley extract, bearskin extract, windbreak herb extract, butterbur extract, soothing extract, chazum extract, noni extract, and mixtures thereof It may include one more.
상기 식품은 일반 식품, 가공식품, 건강기능식품, 기능성 식품을 포함하는 것으로 하며, 예시적으로 상기 식품에 대한 제형으로는 음료, 차, 정제, 육류가공식품, 스낵, 인스턴트식품 등으로 적용될 수 있다.The food is intended to include general foods, processed foods, health functional foods, and functional foods, and exemplary formulations for the food may be applied as beverages, teas, tablets, processed meat foods, snacks, instant foods, etc. .
본 발명에 또 다른 실시예에 따른 허혈성 재관류 손상의 예방 및 개선용 식품은 상기 조성물을 포함하고, 오미자 추출물, 딸기 추출물, 아사이베리 추출물, 아로니아 추출물, 블루베리 추출물, 크랜베리 추출물, 자몽 추출물, 오렌지 추출물, 레몬 추출물, 초코민트 추출물, 바질 추출물, 페퍼민트 추출물, 세이지 추출물, 라벤더 추출물, 파슬리 추출물, 곰피 추출물, 방풍나물 추출물, 머위 추출물, 달래 추출물, 차즈기 추출물, 노니 추출물 및 이들의 혼합물로 이루어진 군에서 어느 하나를 더 포함하는 것일 수 있다.Food for the prevention and improvement of ischemic reperfusion injury according to another embodiment of the present invention comprises the composition, and Schisandra chinensis extract, strawberry extract, acai berry extract, aronia extract, blueberry extract, cranberry extract, grapefruit extract, orange Group consisting of extracts, lemon extracts, chocolate mint extracts, basil extracts, peppermint extracts, sage extracts, lavender extracts, parsley extracts, gompi extracts, windworm extracts, butterbur extract, soothing extracts, chazugi extract, noni extract, and mixtures thereof It may be to include any one more.
바람직하게 상기 식품 또는 건강기능식품은 석창포 추출물 100 중량부에 대하여 오미자 0.1 내지 1 중량부; 크랜베리 추출물 0.1 내지 1 중량부; 페퍼민트 추출물 0.1 내지 2 중량부, 파슬리 추출물 1 내지 3 중량부 및 달래 추출물 0.1 내지 1 중량부를 더 포함하는 것일 수 있다. 상기 범위에 의하는 경우 석창포 추출물이 가진 기호성 낮은 향과 맛이 중화되면서 상당히 깊고 상큼한 향과 함께 기호성을 가진 식감의 식품 조성물로 제공할 수 있다. 특히 상기 범위에 의하는 경우 석창포 추출물에 비하여 10 중량% 미만으로 포함되는 것으로서, 석창포 추출물의 기능성을 해하지 않으면서도 상술한 바와 같이 석창포 추출물의 맛과 향미를 개선하여 상당히 기호성 높은 식품 조성물로 제공하게 할 수 있다. 또한 상술한 곰피 추출물; 방풍나물 추출물 및 차즈기 추출물을 더 하는 경우에도 맛과 향이 우수하여 기호성이 높고, 본 발명에서 목적하는 유효성분의 활성을 최대한 유지하게 할 수 있다는 장점을 가진다.Preferably, the food or health functional food is 0.1 to 1 parts by weight of Schisandra chinensis based on 100 parts by weight of Seokchangpo extract; 0.1 to 1 part by weight of cranberry extract; 0.1 to 2 parts by weight of peppermint extract, 1 to 3 parts by weight of parsley extract, and 0.1 to 1 parts by weight of soothe extract may be further included. In the case of the above range, the low palatability aroma and taste of the Seokchangpo extract can be neutralized, while providing a food composition having a tasteful texture with a fairly deep and refreshing aroma. In particular, if it falls within the above range, it is contained in less than 10% by weight compared to the Seokchangpo extract, and while improving the taste and flavor of the Seokchangpo extract as described above without impairing the functionality of the Seokchangpo extract, it will be provided as a food composition having a fairly high palatability. I can. In addition, the above-described gompi extract; Even in the case of adding the windbreak herb extract and the chazugi extract, the taste and flavor are excellent, so that palatability is high, and the activity of the active ingredient desired in the present invention can be maintained as much as possible.
상기 건강기능식품은 인지기능 또는 기억능력을 개선하거나 허혈성 질환의 예방 또는 개선, 허혈 재관류 손상의 예방 또는 개선시키기 위해 섭취할 수 있는 것이면 특별히 제한되지 않는다.The health functional food is not particularly limited as long as it can be consumed to improve cognitive function or memory ability, prevent or improve ischemic disease, or prevent or improve ischemic reperfusion injury.
본 발명의 건강기능식품 조성물을 식품첨가물로 사용하는 경우, 상기 건강기능식품 조성물을 그대로 첨가하거나 다른 식품 또는 식품성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분은 그의 사용 목적(예방 또는 개선)에 따라 적절하게 사용될 수 있다. 일반적으로, 식품 또는 음료의 제조시 본 발명의 건강기능식품 조성물은 원료에 대하여 15 중량부 이하, 바람직하게는 10 중량부 이하의 양으로 첨가된다. 그러나 건강을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로 사용될 수 있다.When using the health functional food composition of the present invention as a food additive, the health functional food composition may be added as it is or may be used with other foods or food ingredients, and may be appropriately used according to a conventional method. The active ingredient may be appropriately used depending on the purpose of use (prevention or improvement). In general, when preparing food or beverage, the health functional food composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less based on the raw material. However, in the case of long-term intake for health purposes, the amount may be less than the above range, and there is no problem in terms of safety, so the active ingredient may be used in an amount above the above range.
상기 건강기능식품의 종류에 특별한 제한은 없다. 본 발명의 건강기능식품 조성물은 식품, 특히 기능성 식품으로 제조될 수 있다. 본 발명의 기능성 식품은There is no particular limitation on the kind of the health functional food. The health functional food composition of the present invention can be prepared as a food, particularly a functional food. Functional food of the present invention
식품 제조 시에 통상적으로 첨가되는 성분을 포함하며, 예를 들어, 단백질, 탄수화물, 지방, 영양소 및 조미제를 포함한다. 예컨대, 드링크제로 제조되는 경우에는 유효성분 이외에 천연 탄수화물 또는 향미제를 추가 성분으로서 포함시킬 수 있다. 상기 천연 탄수화물은 모노사카라이드(예컨대, 글루코오스, 프럭토오스 등),디사카라이드(예컨대, 말토스, 수크로오스 등), 올리고당, 폴리사카라이드(예컨대, 덱스트린, 시클로덱스트린 등) 또는 당알코올(예컨대, 자일리톨, 소르비톨, 에리쓰리톨 등)인 것이 바람직하다. 상기 향미제는 천연 향미제(예컨대, 타우마틴, 스테비아 추출물 등)와 합성 향미제(예컨대, 사카린, 아스파르탐 등)를 이용할 수 있다.It includes ingredients that are commonly added in food production, and includes, for example, proteins, carbohydrates, fats, nutrients and seasoning agents. For example, when prepared as a drink, natural carbohydrates or flavoring agents may be included as additional ingredients in addition to the active ingredient. The natural carbohydrates are monosaccharides (eg, glucose, fructose, etc.), disaccharides (eg, maltose, sucrose, etc.), oligosaccharides, polysaccharides (eg, dextrins, cyclodextrins, etc.), or sugar alcohols (eg , Xylitol, sorbitol, erythritol, etc.). The flavoring agent may be a natural flavoring agent (eg, taumatin, stevia extract, etc.) and a synthetic flavoring agent (eg, saccharin, aspartame, etc.).
상기 건강기능식품 조성물 이외에 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 더 함유할 수 있다.In addition to the above health functional food composition, various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonic acid It may further contain a carbonation agent used in beverages.
본 발명은 천연물을 기반으로 한 기억력 및 인지기능 개선, 허혈성 질환의 예방 및 개선 효과를 가지는 석창포 추출물을 포함하는 조성물을 제공한다.The present invention provides a composition comprising a seokchangpo extract having an effect of improving memory and cognitive function based on natural products and preventing and improving ischemic diseases.
본 발명은 허혈성 재관류 손상의 예방 및 개선 효과를 가지는 석창포 추출물을 포함하는 조성물을 제공한다.The present invention provides a composition comprising a seokchangpo extract having an effect of preventing and improving ischemic reperfusion injury.
본 발명에 따른 석창포 추출물을 포함하는 조성물은 천연 추출물로서, 세포독성 등의 부작용의 문제가 없어 장기간 사용하면서, 기억력 및 인지기능 개선, 허혈성 재관류 손상의 예방 및 개선 효과를 낼 수 있다.The composition comprising the seokchangpo extract according to the present invention is a natural extract, and it is used for a long time because there is no problem of side effects such as cytotoxicity, and it can improve memory and cognitive function, and prevent and improve ischemic reperfusion injury.
본 발명은 석창포 추출물을 포함하는 기억력 및 인지기능 개선, 허혈성 재관류 손상의 예방 및 개선용 조성물을 식품, 건강기능식품 등의 제형으로 제공할 수 있다.The present invention can provide a composition for improving memory and cognitive function including seokchangpo extract and preventing and improving ischemic reperfusion injury in a formulation such as food and health functional food.
도 1은 본 발명의 일 실시예에 따른 OGD 모델에서 세포 생존율에 관한 것이다.
도 2는 본 발명의 일 실시예에 따른 OGD 모델에서 LDH 발현 평가에 대한 것이다.
도 3은 본 발명의 일 실시예에 따른 OGD 모델에서 활성산소종 변화에 대한 것이다.
도 4는 본 발명의 일 실시예에 따른 OGD 모델에서 활성산소종 변화에 대한 것이다.
도 5는 본 발명의 일 실시예에 따른 OGD 모델에서 환원된 GSH(reduced glutathione) 변화에 대한 것이다.
도 6은 본 발명의 일 실시예에 따른 OGD 모델에서 산화 스트레스에 의한 세포내 활성산화종 변화에 대한 것이다.
도 7은 본 발명의 일 실시예에 따른 OGD 모델에서 항염 활성 평가에 관한 것이다.
도 8은 본 발명의 일 실시예에 따른 OGD 모델에서 허혈성 뇌졸중의 저해활성 평가에 관한 것이다.
도 9는 본 발명의 일 실시예에 따른 세포 보호 활성에 관한 것이다.1 relates to cell viability in an OGD model according to an embodiment of the present invention.
Figure 2 is for the evaluation of LDH expression in the OGD model according to an embodiment of the present invention.
3 is a diagram for a change in reactive oxygen species in the OGD model according to an embodiment of the present invention.
4 is a diagram for a change in reactive oxygen species in the OGD model according to an embodiment of the present invention.
5 is a diagram for a change in reduced glutathione (GSH) in an OGD model according to an embodiment of the present invention.
6 is a graph of changes in intracellular active oxidized species due to oxidative stress in the OGD model according to an embodiment of the present invention.
7 relates to the evaluation of anti-inflammatory activity in the OGD model according to an embodiment of the present invention.
Figure 8 relates to the evaluation of the inhibitory activity of ischemic stroke in the OGD model according to an embodiment of the present invention.
9 is related to the cell protective activity according to an embodiment of the present invention.
이하, 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있도록 본 발명의 실시예에 대하여 상세히 설명한다. 그러나 본 발명은 여러 가지 상이한 형태로 구현될 수 있으며 여기에서 설명하는 실시예에 한정되지 않는다.Hereinafter, embodiments of the present invention will be described in detail so that those skilled in the art can easily implement the present invention. However, the present invention may be implemented in various different forms and is not limited to the embodiments described herein.
[제조예 1: 석창포 추출물의 제조][Production Example 1: Preparation of Seokchangpo Extract]
석창포를 세척 및 건조하고, 분쇄한 뒤 열수 추출하고, 농축 여과하여 석창포 추출물(WAGS)을 제조하였다. 상기 석창포 추출물을 일정한 농도로 희석하면서 이하의 실험을 진행하였다.The seokchangpo was washed and dried, pulverized, extracted with hot water, and concentrated and filtered to prepare seokchangpo extract (WAGS). The following experiment was conducted while diluting the Seokchangpo extract to a certain concentration.
[실험예 1: OGD 모델을 통한 허혈 재류관 손상 예방 및 개선활성 실험][Experimental Example 1: Prevention and improvement activity test for ischemic reentry damage through OGD model]
1. OGD 모델의 구성 및 세포배양1. OGD model composition and cell culture
제조예에 따른 추출물에 대한 허혈 재관류 손상을 완화 효과를 확인하기 위하여 세포에 산소-혈당 결핍(Oxygen glucose deprivation, OGD) 실험법을 통하여 허혈의 시험 관내 모델을 확립하였다. 한편, 인간 신경아세포종 SH-SY5Y cell(ATCC no. CRL-2266)은 10% fetal bovine serum(Gibco-BRL, USA) 및 antibiotics(Sigma-Aldrich, USA)가 함유된 dulbecco's modified eagle's medium(Sigma-Aldrich, USA) 배지하에서 배양하였다. 배양기는 37℃ 온도를 유지했고 공기 95v%와 CO2 5v%가 혼합된 기체가 계속 공급되어 세포 배양의 적절한 조건을 갖추었다.In order to confirm the effect of alleviating the ischemia reperfusion injury of the extract according to the preparation example, an in vitro model of ischemia was established through an oxygen-glycemic deprivation (OGD) test on cells. On the other hand, human neuroblastoma SH-SY5Y cell (ATCC no. CRL-2266) is dulbecco's modified eagle's medium (Sigma-Aldrich) containing 10% fetal bovine serum (Gibco-BRL, USA) and antibiotics (Sigma-Aldrich, USA). , USA) cultured in medium. The incubator was maintained at a temperature of 37°C, and a gas mixed with 95v% of air and 5v% of CO 2 was continuously supplied to obtain appropriate conditions for cell culture.
2. 석창포 추출물의 세포 생존율 분석2. Analysis of cell viability of Seokchangpo extract
세포 생존율을 분석하기 위해 처리된 인간신경세포(SH-SY5Y)를 6-웰 플레이트(6-well plate)에 3 x 105 cells/ml로 접종하고 24시간 동안 배양한 후 다양한 농도의 WAGS을 처리한 뒤 24시간동안 배양하였다. In order to analyze cell viability, treated human neurons (SH-SY5Y) were inoculated into a 6-well plate at 3 x 10 5 cells/ml, incubated for 24 hours, and then treated with WAGS at various concentrations. And then incubated for 24 hours.
그 결과 실험이 진행된 10 내지 500 μg/ml의 범위에서 WAGS를 처리한 결과 WAGS은 세포 생존율에 별다른 영향을 주지 않는다는 점을 확인할 수 있었다.As a result, as a result of treatment with WAGS in the range of 10 to 500 μg/ml in which the experiment was conducted, it was confirmed that WAGS did not significantly affect cell viability.
3. 산소-혈당 결핍(oxygen glucoside privation, OGD)과 세포 생존율 및 LDH 분석3. Oxygen glucoside privation (OGD), cell viability and LDH analysis
OGD 유도에 의한 세포 사멸은 일시적으로 영양분과 산소의 공급을 차단함으로써 세포에 산화적 스트레스가 유발되고 다시 영양분과 산소를 재공급 함으로써 세포의 사멸을 유도하는 방법으로, 실제 임상학적 뇌허혈 발생을 반영한 환경이라 할 수 있다. 활성 산소종이 직접 세포 손상을 유도하거나, 신호전달체계를 통해 간접적으로 세포손상을 일으킬 수 있다. 이러한 활성 산소종은 뇌졸중을 포함한 여러 중추신경계 질환 및 다양한 퇴행성 뇌질환에서 병인론적으로 중요한 역할을 한다. 인간 신경아세포종 SH-SY5Y 세포에 인위적으로 포도당과 혈청의 공급을 중단하고 산소가 결핍된 환경을 만들어, 세포 사멸을 유도하기 위하여 OGD 모델을 통하여 혈액의 공급 중단에 따른 허혈 상태와 유사한 환경을 설정해 주어, 허혈 상태에 따른 뇌 신경세포 사멸을 유도하면서, WAGS 투여에 따른 세포생존율을 평가하였다. 그 결과를 하기의 도 1을 참조하면, OGD 모델에서도 WAGS를 처리한 경우 농도 의존적으로 세포 생존율이 향상된다는 것을 알 수 있다.Cell death by OGD induction is a method of inducing cell death by temporarily blocking the supply of nutrients and oxygen, causing oxidative stress in cells and resupplying nutrients and oxygen to induce cell death. It can be called this. Reactive oxygen species can induce cell damage directly or indirectly through a signaling system. These reactive oxygen species play an important etiological role in various central nervous system diseases including stroke and various degenerative brain diseases. Human neuroblastoma SH-SY5Y In order to artificially stop supplying glucose and serum to cells and create an oxygen-deficient environment, and to induce cell death, an environment similar to the ischemic condition caused by the interruption of blood supply is set through the OGD model. , While inducing brain neuron death according to the ischemic state, the cell viability according to WAGS administration was evaluated. Referring to FIG. 1 for the results, it can be seen that in the case of treatment with WAGS in the OGD model, cell viability is improved in a concentration-dependent manner.
한편, 상기 OGD 모델에서 혈청 LDH(lactate dehydrogenase) 활성은 ELISA법으로 측정하여 확인하였다. LDH는 허혈성 재관류 손상에 대한 대표적인 지표성분으로서, 하기의 도 2를 참조하면 WAGS를 처리한 경우 농도 의존적으로 그 발현 수준이 감소하는 것으로 알 수 있다.Meanwhile, serum LDH (lactate dehydrogenase) activity in the OGD model was measured and confirmed by ELISA. LDH is a representative indicator component for ischemic reperfusion injury, and referring to FIG. 2 below, it can be seen that the expression level thereof decreases in a concentration-dependent manner when WAGS is treated.
4. 효소활성의 측정4. Measurement of enzyme activity
OGD 모델에 있어 석창포 추출물(WAGS)에 따른 외부 산화 스트레스에 의한 세포 내 활성산소종의 변화를 알아보기 위하여 말론디알데하이드(MDA)을 측정하기 위하여 TBARS법을 사용하였다. 슈퍼옥사이드 디스뮤타제(SOD)의 활성을 평가하기 위하여 SOD Assay Kit를 사용하였고, 글루타티온 퍼옥시다제(GPx)의 활성도는 Glutathione peroxidas cellular Activity Assay Kit를 사용하여 측정하였다. In the OGD model, the TBARS method was used to measure malondialdehyde (MDA) in order to investigate the change of intracellular reactive oxygen species due to external oxidative stress according to seokchangpo extract (WAGS). The SOD Assay Kit was used to evaluate the activity of superoxide dismutase (SOD), and the activity of glutathione peroxidase (GPx) was measured using the Glutathione peroxidas cellular Activity Assay Kit.
그 결과를 하기의 도 3 내지 도 5에 나타내었다. 상기 도 3 내지 5를 참조하면, WAGS은 OGD 모델에 의하여 유도된 산화 스트레스를 농도 유의적으로 감소시킬 수 있다는 점을 확인할 수 있다.The results are shown in FIGS. 3 to 5 below. Referring to FIGS. 3 to 5, it can be seen that WAGS can significantly reduce oxidative stress induced by the OGD model in concentration.
또한, OGD 모델에서 산화 스트레스에 의한 세포 내 활성산소종의 변화를 알아보기 위하여 활성산소종과 결합하면 탈아세틸화되어 형광을 띄는 dichlorodihydro-fluorescein diacetate (DCF-DA)를 사용하여 세포내 활성산소종의 발생 정도를 측정하였다. 하기의 도 6에 나타내었다. 상기 도 6을 참조하면 WAGS은 OGD 모델에 의하여 유도된 산화 스트레스가 농도 의존적으로 감소하는 것을 알 수 있다.In addition, in the OGD model, dichlorodihydro-fluorescein diacetate (DCF-DA), which is deacetylated and fluorescent when combined with reactive oxygen species, is used to investigate changes in intracellular reactive oxygen species caused by oxidative stress. The degree of occurrence of was measured. It is shown in Figure 6 below. Referring to FIG. 6, it can be seen that the oxidative stress induced by the OGD model in WAGS decreases in a concentration-dependent manner.
5. 항염 활성 평가5. Anti-inflammatory activity evaluation
사이토카인은 면역반응, 감염, 외상, 염증 등에 대한 반응을 조절하고 세포와 세포 사이의 신호를 전달하는 물질이다. 친염증성 사이토카인은 IL-1 (IL-1α, β), IL-6, IL-8, TNF-α, G-CSF, GM-CSF, interferon (IFN)-γ, CXCL1, CXCL2 등이 있으며 염증을 유발하고 상승시키는 데 중요한 역할을 하고 세포손상을 매개하며, 허혈과 재관류가 일어나는 동안 허혈조직과 허혈되지 않은 다른 장기들은 친염증성 사이토카인을 생성하고, 이들은 염증세포의 축적을 유도하여 장기에 염증과 손상을 유발시키기도 한다.Cytokines are substances that control immune responses, infections, trauma, and inflammation, and transmit signals between cells. Pro-inflammatory cytokines include IL-1 (IL-1α, β), IL-6, IL-8, TNF-α, G-CSF, GM-CSF, interferon (IFN)-γ, CXCL1, CXCL2, etc. During ischemia and reperfusion, ischemic tissue and other non-ischemic organs produce pro-inflammatory cytokines, which induces the accumulation of inflammatory cells and causes inflammation in the organ. It can also cause overload and damage.
특히 염증반응은 허혈-재관류 손상의 요인 중 하나로 알려져 있다. 따라서, OGD 모델에 있어서, 석창포 추출물(WAGS)에 따른 NO 및 염증성 사이토카인의 발현을 평가하여 하기의 도 7에 나타내었다.In particular, the inflammatory reaction is known to be one of the causes of ischemia-reperfusion injury. Therefore, in the OGD model, the expression of NO and inflammatory cytokines according to the seokchangpo extract (WAGS) was evaluated and shown in FIG. 7 below.
하기의 도 7을 참조하면, 석창포 추출물(WAGS)에 의하는 경우 OGD 모델에 있어 농도 의존적으로 항염활성이 높아지는 것으로 알 수 있다. 이에 따라 상기 석창포 추출물(WAGS)에 의하는 경우 염증에 의한 허혈-재관류 손상에 대한 예방 또는 개선될 수 있다는 것을 확인할 수 있다.Referring to FIG. 7 below, it can be seen that the anti-inflammatory activity is increased in a concentration-dependent manner in the OGD model in the case of seokchangpo extract (WAGS). Accordingly, it can be confirmed that the seokchangpo extract (WAGS) can prevent or improve ischemia-reperfusion damage caused by inflammation.
5. 허혈성 뇌졸중의 저해활성 평가5. Evaluation of inhibitory activity of ischemic stroke
허혈성 뇌졸중(ischemic stroke)이 혈관성 치매와 알츠하이머성 치매의 발병에 중요한 요인으로 작용한다. Ischemic stroke is an important factor in the development of vascular dementia and Alzheimer's dementia.
이러한 치매 환자의 뇌에서 공통적으로 plaque 형태로 과량 침착되며 뇌조직 퇴행의 원인으로 지목된 Aβ는 β-secretase와 γ-secretase가 APP에 순차적으로 작용해 생성된다. 특히 plaque은 APP 단백질을 잘려서 생성된 40 내지 42개의 아미노산으로 이뤄진 Aβ를 주성분으로 한다.In the brains of these dementia patients, Aβ, which is commonly deposited in the form of plaques, and is identified as the cause of brain tissue degeneration, is produced by the sequential action of β-secretase and γ-secretase on APP. In particular, plaque is based on Aβ consisting of 40 to 42 amino acids produced by cleaving the APP protein.
Aβ는 크게 두 종류가 있으며, 그 중 Aβ40는 정상인의 뇌에서도 노화에 따라 증가하지만 높은 신경독성을 지닌 Aβ42는 치매 환자 뇌에서 특이적으로 증가한다. 바로 γ-secretase cleavage에 의해 Aβ40와 Aβ42의 생성이 결정된다. 한편, β-secretase는 치매 환자의 뇌조직에서 발현이 증가한다. 특히, 산화적 스트레스에 의한 β-secretase 발현의 증가가 매우 뚜렷하며 이러한 산화스트레스에 의한 β-secretase의 발현은 γ-secretase의 활성에 의존적이다.There are two main types of Aβ, of which Aβ 40 increases with aging in the brain of normal people, but Aβ 42 with high neurotoxicity increases specifically in the brain of dementia patients. Immediately, the production of Aβ 40 and Aβ 42 is determined by γ-secretase cleavage. Meanwhile, the expression of β-secretase is increased in the brain tissue of dementia patients. In particular, the increase in β-secretase expression by oxidative stress is very pronounced, and expression of β-secretase by oxidative stress is dependent on the activity of γ-secretase.
따라서, 상기 OGD 모델에 있어 석창포 추출물(WAGS)을 처리하면서, Aβ40와 Aβ42 펩타이드의 생성과 β-secretase 및 γ-secretase 발현 정도를 평가하여 하기의 도 8에 나타내었다.Therefore, in the OGD model, while treating the seokchangpo extract (WAGS), the generation of Aβ 40 and Aβ 42 peptides and the expression levels of β-secretase and γ-secretase were evaluated and shown in FIG. 8 below.
하기의 도 8을 참조하면, 상기 OGD 모델에서 WAGS에 의하는 경우 농도 의존적으로 Aβ40와 Aβ42의 생성량이 감소하는 것을 알 수 있다. 또한, β-secretase 및 γ-secretase 발현의 감소하는 점을 알 수 있다. 이에 따라 상기 석창포 추출물(WAGS)에 의하는 경우 허혈성 뇌졸중에 대한 예방 또는 개선을 통하여 이에 따른 혈관성 치매 또는 알츠하이머성 치매의 발병을 예방 및 개선할 수 있다는 것을 확인하였다.Referring to FIG. 8 below, in the case of WAGS in the OGD model, it can be seen that the amount of production of Aβ 40 and Aβ 42 decreases in a concentration-dependent manner. In addition, it can be seen that the expression of β-secretase and γ-secretase is decreased. Accordingly, it was confirmed that the occurrence of vascular dementia or Alzheimer's dementia can be prevented and improved through the prevention or improvement of ischemic stroke in the case of the seokchangpo extract (WAGS).
6. 아포토시스 세포 사멸6. Apoptosis cell death
세포 아포토시스는 유세포 분석법 (BD, Mountain View, USA)을 통하여 진행하였다. 그 결과를 하기의 도 9에 나타내었다. 하기의 도 9를 참조하면, OGD 모델에서 WAGS을 처리한 경우 신경 세포 사멸이 방지되는 것을 확인할 수 있다.Cell apoptosis was performed through flow cytometry (BD, Mountain View, USA). The results are shown in FIG. 9 below. Referring to FIG. 9 below, it can be seen that nerve cell death is prevented when WAGS is treated in the OGD model.
결국, 상기 석창포 추출물(WAGS)은 인간신경세포(SH-SY5Y)에서 외부 산화 스트레스에 대한 저항활성을 가지게 하고, 미토콘드리아 손상 및 세포 사멸을 억제하여 미토콘드라아 의존성 아포토시스(Apoptosis) 경로를 억제하여 허혈 재관류 손상을 완화할 수 있다는 점을 확인할 수 있었다.Eventually, the seokchangpo extract (WAGS) has resistance to external oxidative stress in human neurons (SH-SY5Y), inhibits mitochondrial damage and cell death, thereby inhibiting the mitochondrial-dependent apoptosis pathway. It was confirmed that the ischemic reperfusion injury can be alleviated.
[제조예 2: 혼합 추출물의 제조][Production Example 2: Preparation of mixed extract]
상기와 WAGS과 동일한 방법에 따라 열수추출을 통하여, 곰피 추출물(SGP), 방풍나무 추출물(SDS), 차즈기 추출물(SPF), 원지 추출물(SPT), 오미자 추출물(E1), 크랜베리 추출물(E2), 페퍼민트 추출물(E3), 파슬리 추출물(E4) 및 달래 추출물(E5)를 제조하고 각 추출물을 하기의 [표 1]과 같은 조성에 따라 혼합 조성을 제조하였다.Through hot water extraction according to the same method as above and WAGS, gompi extract (SGP), perspex extract (SDS), chazugi extract (SPF), raw paper extract (SPT), Schisandra chinensis extract (E1), cranberry extract (E2) , Peppermint extract (E3), parsley extract (E4), and soothe extract (E5) were prepared, and a mixed composition was prepared according to the composition shown in [Table 1] for each extract.
(단위: 중량부)(Unit: parts by weight)
[실험예 2: 기억력 및 인지기능 개선 효과 실험][Experimental Example 2: Experiment on the effect of improving memory and cognitive function]
1. DPPH radical 분석1. DPPH radical analysis
생체에서 산화적 스트레스와 관련되어 있는 DPPH, superoxide anion과 같은 활성산소종에 대한 분석을 위하여 1,1-Diphenyl-2-picrylhydrazyl (DPPH) radical을 이용하여 WAGS 및 M1 내지 M6의 radical 소거능력을 측정하였다. WAGS 및 M1 내지 M6에 DPPH 용액을 가하여 반응시킨 후 흡광도를 측정하였다. DPPH radical 함량은 시료 첨가군과 대조군의 흡광도 비를 %값으로 환산하여 [표 2] 나타내었다.Measure the radical scavenging ability of WAGS and M1 to M6 using 1,1-Diphenyl-2-picrylhydrazyl (DPPH) radical for analysis of reactive oxygen species such as DPPH and superoxide anion, which are related to oxidative stress in vivo. I did. After reacting by adding a DPPH solution to WAGS and M1 to M6, absorbance was measured. DPPH radical content is shown in [Table 2] by converting the absorbance ratio of the sample addition group and the control group to a% value.
2. 환원력 분석2. Analysis of reducing power
Superoxide anion 라디칼 소거능은 Fridovich법에 따라 진행하였다. 시료 1 ml에 pH 6.6의 200 mM 인산 완충액 및 potassium ferricyanide를 각각 1 ml씩 차례로 가하여 반응시켰다. 여기에 10% TCA (trichloroacetic acid)용액을 상등액에 증류수 및 ferric chloride 혼합한 후 흡광도를 측정하였다. WAGS 및 M1 내지 M6은 대조군의 값을 기준으로 흡광도 비를 %값으로 환산하여 하기의 [표 3]에 나타내었다.Superoxide anion radical scavenging activity was performed according to the Fridovich method. To 1 ml of the sample, 200 mM phosphate buffer and potassium ferricyanide having a pH of 6.6 were sequentially added to each of 1 ml for reaction. Here, a 10% TCA (trichloroacetic acid) solution was mixed with distilled water and ferric chloride in the supernatant, and the absorbance was measured. WAGS and M1 to M6 are shown in Table 3 below by converting the absorbance ratio into% values based on the values of the control group.
3. Hydroxyl radical에 의한 DNA 손상 분석3. DNA damage analysis by hydroxy radical
Genomic DNA는 약간 변형된 표준 과정에 따라 PC12 세포로부터 추출하였다. DNA 용액에 WAGS 및 M1 내지 M6와 200 μM FeSO4, 1 mM H2O2 및 50 μg/ml genomic DNA를 첨가하였다. 반응 종결 후 전기영동 하였다. 염색하여 후 UV로 LAS3000 image analyzer를 이용하여 관찰하였고, 무처리군을 기준으로 그 결과를 %화 하여 하기의 [표 4]에 나타내었고, 그 % 수치가 낮을수록 우수한 것이다.Genomic DNA was extracted from PC12 cells according to a slightly modified standard procedure. WAGS and M1 to M6, 200 μM FeSO4, 1 mM H2O2, and 50 μg/ml genomic DNA were added to the DNA solution. After completion of the reaction, electrophoresis was performed. After dyeing, it was observed using a LAS3000 image analyzer with UV, and the results were converted to% based on the untreated group and shown in Table 4 below, and the lower the% value, the better.
4. ACE (Angiotensin I Converting Enzyme) 활성 측정4. ACE (Angiotensin I Converting Enzyme) activity measurement
ACE 활성은 WAGS 및 M1 내지 M6에 각각 붕산나트륨 완충액(pH 8.3)과 ACE 조효소액 가하여 예비반응을 진행한 후 시킨 후, HHL(hippuryl-histidyl-leucine)을 첨가하여 만든 기질을 가하여 반응하였다. 한편, ACE 조효소액은 sodium borate buffer (pH 8.3)에 rabbit lung acetone powder을 추출한 다음 원심분리하여 제조하였다. 반응 후 채취한 상등액을 건조 및 증류수를 혼합하고 흡광도를 측정하였다. 음성대조군으로는 증류수를 사용하였으며, 무처리군을 기준(100%)으로 시료 첨가 전후의 흡광도 비를 %값으로 환산하여 하기의 [표 5]에 나타내었다.ACE activity was performed after pre-reaction by adding sodium borate buffer (pH 8.3) and ACE coenzyme solution to WAGS and M1 to M6, respectively, and then reacted by adding a substrate made by adding HHL (hippuryl-histidyl-leucine). Meanwhile, the ACE coenzyme solution was prepared by extracting rabbit lung acetone powder in sodium borate buffer (pH 8.3) and then centrifuging. The supernatant collected after the reaction was dried and mixed with distilled water, and the absorbance was measured. Distilled water was used as the negative control group, and the absorbance ratio before and after the addition of the sample was converted into a% value based on the untreated group (100%), and is shown in Table 5 below.
5. AChE (Acetylcholine esterase) 활성측정5. AChE (Acetylcholine esterase) activity measurement
PC12 세포로부터 분리한 AchE (25 mU/ml) 50μl를 반응효소로, 0.1 M의 인산나트륨 완충액(pH 7.8)에 녹인 아세틸콜린 요오드화물을 기질로 하였고, 발색 시약은 5,5'-dithiobis-2-nitrobenzoic acid 및 탄산수소나트륨을 0.1 M 인산나트륨 완충액(pH 7.0) 10 ml에 용해하여 제조하였다. 반응 후, 분광광도계로 412 nm에서 흡광도 값을 측정하였다. AChE의 활성은 무처리군을 기준(100%)으로 WAGS 및 M1 내지 M6의 첨가 전후의 흡광도 비를 %값으로 환산하여 하기의 [표 6]에 나타내었다.50 μl of AchE (25 mU/ml) isolated from PC12 cells was used as a reaction enzyme, and acetylcholine iodide dissolved in 0.1 M sodium phosphate buffer (pH 7.8) was used as a substrate, and the color developing reagent was 5,5'-dithiobis-2. -nitrobenzoic acid and sodium hydrogen carbonate were prepared by dissolving in 10 ml of 0.1 M sodium phosphate buffer (pH 7.0). After the reaction, the absorbance value was measured at 412 nm with a spectrophotometer. The activity of AChE is shown in [Table 6] below by converting the absorbance ratio before and after the addition of WAGS and M1 to M6 to a% value based on the untreated group (100%).
6. C12세포에서 NF-κB 전사활성에 대한 시험6. Test for NF-κB transcriptional activity in C12 cells
PC12 cells을 배양하면서 NF-κB promoter-luciferase construct를 이용하여 NF-κB의 전사 활성을 평가하여 WAGS 및 M1 내지 M6에 대한 C12세포에서 NF-κB 전사활성에 대한 영향을 비교하였다. WAGS의 결과를 10으로 하고, M1 내지 M6의 결과를 지수로 평가하여 [표 7]에 나타내었다. 상기 지수가 높을수록 NF-κB의 전사 활성이 우수한 것이다.While culturing PC12 cells, the NF-κB promoter-luciferase construct was used to evaluate the transcriptional activity of NF-κB, and the effects on NF-κB transcriptional activity in WAGS and C12 cells against M1 to M6 were compared. The WAGS result was set to 10, and the results of M1 to M6 were evaluated as an index, and are shown in [Table 7]. The higher the index, the better the transcriptional activity of NF-κB.
결국 본 발명에 의하는 경우 활성산소종의 제거, DNA 손상에 대한 항산화, ACE(Angiotensin Converting Enzyme) 효소 저해활성, AChE(acetylcholine esterase) 저해 활성, NO(Nitric oxide) 생성 억제활성, NF-κB 전사활성 증가효과가 나타난다는 점을 확인할 수 있다. 또한 M2 내지 M4의 혼합조성과 M6에 의하는 경우 일정한 상승효과가 나타나는 점을 알 수 있다.In the end, according to the present invention, removal of reactive oxygen species, antioxidant against DNA damage, ACE (Angiotensin Converting Enzyme) enzyme inhibitory activity, AChE (acetylcholine esterase) inhibitory activity, NO (Nitric oxide) production inhibitory activity, NF-κB transcription It can be seen that the effect of increasing the activity appears. In addition, it can be seen that a certain synergistic effect appears when the mixture composition of M2 to M4 and M6 are used.
따라서 상기 석창포 추출물 또는 석창포 추출물에 대한 혼합구성을 기초로, 기억력 및 두뇌 인지기능 개선을 위한 효과를 낼 수 있는 다양한 제품에 적용시킬 수 있다.Therefore, it can be applied to various products that can produce an effect for improving memory and brain cognitive function based on the mixture composition of the seokchangpo extract or seokchangpo extract.
[실험예 3: 기호성 평가][Experimental Example 3: Evaluation of palatability]
WAGS 및 상기 T1 내지 T5의 조성에 따라 차 음료를 제조하고, 10인의 시험자에게 시음하게 한 뒤 향과 맛을 평가하게 하여 1 내지 10의 기호도를 평가하도록 하였다. 그 결과를 종합하여 평균한 뒤 하기의 [표 8]에 나타내었다. 하기의 지수는 그 숫자가 높을 수록 기호도가 우수한 것이다(각 지수는 평균 값에 반올림을 적용하였다).A tea beverage was prepared according to WAGS and the composition of T1 to T5, and 10 testers were made to taste it, and then the aroma and taste were evaluated to evaluate the acceptability of 1 to 10. The results are summarized and averaged, and then shown in Table 8 below. The following indices are the higher the number, the better the preference (each indices are rounded off to the average value).
(단위: 지수)(Unit: index)
상기 기호성 평가 결과 대부분의 시음자들이 석창포의 향과 맛에 대한 기호성을 낮게 평가하였다. 다만, T2 및 T3의 혼합조성에 의하는 경우 전체적으로 달고 상큼한 향과 석창포 고유의 향미가 은은하게 느껴지면서 전체적으로 맛과 향이 우수하게 되는 점을 확인할 수 있었다. 특히 상기 혼합 조성에 의하는 경우 E1 내지 E5의 혼합물이 석창포 추출물에 대하여 10 중량% 미만으로 포함되기 때문에 석창포의 유효성분에 따른 활성을 최대한 유지하면서도 기호성이 우수할 수 있다. 또한 상기 조성에 의하는 경우 M3에 대한 조성에 있어서도 기호성을 향상시키는 효과를 낼 수 있다는 점을 알 수 있다.As a result of the palatability evaluation, most of the tasters evaluated the palatability of Seokchangpo with low taste. However, in the case of the mixed composition of T2 and T3, it was confirmed that the overall taste and aroma became excellent while the whole sweet and refreshing scent and the unique flavor of Seokchangpo were felt subtly. In particular, in the case of the above mixture composition, since the mixture of E1 to E5 is contained in an amount of less than 10% by weight with respect to the seokchangpo extract, while maintaining the activity according to the active ingredient of seokchangpo as much as possible, palatability may be excellent. In addition, it can be seen that in the case of the above composition, an effect of improving palatability can be achieved even in the composition for M3.
한편, T5의 경우 E1 내지 E5의 혼합물을 사용하는 경우에도 원지 자체의 쓴맛이 중화되지 않아 기호성이 상당히 낮아 소량의 식물 추출물을 혼합하여 기호성 있는 식품 조성물로 제공하는데 어려움이 있을 수 있다.On the other hand, in the case of T5, even when a mixture of E1 to E5 is used, the bitter taste of the base paper itself is not neutralized, so the palatability is considerably low, and it may be difficult to mix a small amount of plant extract to provide a palatable food composition.
이상에서 본 발명의 바람직한 실시예에 대하여 상세하게 설명하였지만 본 발명의 권리범위는 이에 한정되는 것은 아니고 다음의 청구범위에서 정의하고 있는 본 발명의 기본 개념을 이용한 당업자의 여러 변형 및 개량 형태 또한 본 발명의 권리범위에 속하는 것이다.Although the preferred embodiments of the present invention have been described in detail above, the scope of the present invention is not limited thereto, and various modifications and improvements by those skilled in the art using the basic concept of the present invention defined in the following claims are also present. It belongs to the scope of rights of
Claims (6)
상기 석창포 추출물 100 중량부에 대하여 곰피 추출물 1 내지 5 중량부;
방풍나물 10 내지 20 중량부; 및
차즈기 추출물 1 내 5 중량부
를 포함하는
기억력 또는 인지기능 개선용 조성물.Seokchangpo extract;
1 to 5 parts by weight of Gompi extract based on 100 parts by weight of the Seokchangpo extract;
10 to 20 parts by weight of windbreak herbs; And
Chazugi extract 1 in 5 parts by weight
Including
A composition for improving memory or cognitive function.
상기 추출물은 물, 탄소수 1 내지 10의 알코올 및 이들의 혼합물로 이루어진 군에서 선택된 어느 하나를 용매로 추출된 것인
기억력 또는 인지기능 개선용 조성물.The method of claim 1,
The extract is one selected from the group consisting of water, alcohols having 1 to 10 carbon atoms, and mixtures thereof, extracted with a solvent.
A composition for improving memory or cognitive function.
오미자 추출물, 딸기 추출물, 아사이베리 추출물, 아로니아 추출물, 블루베리 추출물, 크랜베리 추출물, 자몽 추출물, 오렌지 추출물, 레몬 추출물, 초코민트 추출물, 바질 추출물, 페퍼민트 추출물, 세이지 추출물, 라벤더 추출물, 파슬리 추출물, 머위 추출물, 달래 추출물, 노니 추출물 및 이들의 혼합물로 이루어진 군에서 선택된 어느 하나를 더 포함하는 것인
기억력 또는 인지기능 개선용 식품.Comprising the composition according to claim 1,
Schisandra chinensis extract, strawberry extract, acai berry extract, aronia extract, blueberry extract, cranberry extract, grapefruit extract, orange extract, lemon extract, chocolate mint extract, basil extract, peppermint extract, sage extract, lavender extract, parsley extract, butterbur Which further comprises any one selected from the group consisting of extract, soothe extract, noni extract, and mixtures thereof
Food for improving memory or cognitive function.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200065703A KR102217607B1 (en) | 2020-06-01 | 2020-06-01 | A composition for improving memory and cognitive function, preventing and improving ischemia reperfusion injury including acorus gramineus soland extract |
KR1020200121691A KR102296272B1 (en) | 2020-06-01 | 2020-09-21 | A composition for improving memory and cognitive function, preventing and improving ischemia reperfusion injury including acorus gramineus soland extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200065703A KR102217607B1 (en) | 2020-06-01 | 2020-06-01 | A composition for improving memory and cognitive function, preventing and improving ischemia reperfusion injury including acorus gramineus soland extract |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200121691A Division KR102296272B1 (en) | 2020-06-01 | 2020-09-21 | A composition for improving memory and cognitive function, preventing and improving ischemia reperfusion injury including acorus gramineus soland extract |
Publications (2)
Publication Number | Publication Date |
---|---|
KR102217607B1 true KR102217607B1 (en) | 2021-02-18 |
KR102217607B9 KR102217607B9 (en) | 2022-03-15 |
Family
ID=74688551
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200065703A KR102217607B1 (en) | 2020-06-01 | 2020-06-01 | A composition for improving memory and cognitive function, preventing and improving ischemia reperfusion injury including acorus gramineus soland extract |
KR1020200121691A KR102296272B1 (en) | 2020-06-01 | 2020-09-21 | A composition for improving memory and cognitive function, preventing and improving ischemia reperfusion injury including acorus gramineus soland extract |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200121691A KR102296272B1 (en) | 2020-06-01 | 2020-09-21 | A composition for improving memory and cognitive function, preventing and improving ischemia reperfusion injury including acorus gramineus soland extract |
Country Status (1)
Country | Link |
---|---|
KR (2) | KR102217607B1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020087721A (en) * | 2001-05-16 | 2002-11-23 | 김호철 | Extract of Acorus gramineus Soland having neuroprotective effects and pharmaceutical composition containing the same |
KR100804480B1 (en) * | 2006-04-27 | 2008-02-20 | 한국과학기술연구원 | A composition for improving memory |
KR20080098001A (en) | 2005-12-21 | 2008-11-06 | 파밍 인텔렉츄얼 프라퍼티 비.브이. | Use of c1 inhibitor for the prevention of ischemia-reperfusion injury |
KR20130097537A (en) * | 2012-02-24 | 2013-09-03 | 동의대학교 산학협력단 | Composition comprising mixture of hot water extract of curcuma longa radix, acorus gramineus soland and polygala tenuifolia to enhance cognition and memory |
KR20150043867A (en) * | 2013-10-15 | 2015-04-23 | 부산대학교 산학협력단 | Composition for preventing or treating brain disease or neural disease comprising oriental herbal extracts |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040064240A (en) * | 2003-01-09 | 2004-07-16 | 학교법인 인제학원 | Herbal composition comprising the extract of Acorus gramineus Soland and Gastrodia elata Blume having inhibitory activity of death of brain neuronal cell |
KR20130105077A (en) * | 2012-03-16 | 2013-09-25 | 동국대학교 경주캠퍼스 산학협력단 | Methylene chlorode fraction isolated from the concentrated extract of polyherbal medicine and composition for prevention and treatment of ischemic stroke comprising the same |
-
2020
- 2020-06-01 KR KR1020200065703A patent/KR102217607B1/en active IP Right Grant
- 2020-09-21 KR KR1020200121691A patent/KR102296272B1/en active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020087721A (en) * | 2001-05-16 | 2002-11-23 | 김호철 | Extract of Acorus gramineus Soland having neuroprotective effects and pharmaceutical composition containing the same |
KR20080098001A (en) | 2005-12-21 | 2008-11-06 | 파밍 인텔렉츄얼 프라퍼티 비.브이. | Use of c1 inhibitor for the prevention of ischemia-reperfusion injury |
KR100804480B1 (en) * | 2006-04-27 | 2008-02-20 | 한국과학기술연구원 | A composition for improving memory |
KR20130097537A (en) * | 2012-02-24 | 2013-09-03 | 동의대학교 산학협력단 | Composition comprising mixture of hot water extract of curcuma longa radix, acorus gramineus soland and polygala tenuifolia to enhance cognition and memory |
KR20150043867A (en) * | 2013-10-15 | 2015-04-23 | 부산대학교 산학협력단 | Composition for preventing or treating brain disease or neural disease comprising oriental herbal extracts |
Also Published As
Publication number | Publication date |
---|---|
KR102217607B9 (en) | 2022-03-15 |
KR102296272B1 (en) | 2021-08-31 |
KR102296272B9 (en) | 2022-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101789424B1 (en) | Medicinal-Herb Composition Comprising Chinese matrimony vine Proving Insomniac and the Method of Making the Same | |
KR102191500B1 (en) | A composition for improving memory and cognitive function, preventing and improving ischemia reperfusion injury including stachys sieboldii miq extract | |
KR20160147132A (en) | A composition comprising the Leaves of Schisandra chinensis for preventing or treating Parkinson's disease or neurodegenerative disease | |
JP2012131754A (en) | Antithrombotic agent | |
KR102369924B1 (en) | Composition for prevention, improvement or treatment of inflammatory diseases comprising an extract of Campanula takesimana Nakai as and active ingredient | |
KR20120031695A (en) | A composition comprising the extract of diospyros kaki thunb as an active ingredient for preventing and treating inflammatory disease | |
KR102217607B1 (en) | A composition for improving memory and cognitive function, preventing and improving ischemia reperfusion injury including acorus gramineus soland extract | |
KR20190135245A (en) | Composition for anti-oxidation, skin whitening comprising Spartina alterniflora extracts as an active ingredient | |
KR20180064077A (en) | A composition comprising ganoderma lucidum grown on hulled barley extracts having anti-oxidation or anti-inflammation activity | |
KR102191452B1 (en) | A COMPOSITION FOR IMPROVING MEMORY AND COGNITIVE FUNCTION, PREVENTING AND IMPROVING ISCHEMIA REPERFUSION INJURY INCLUDING dried persimmon EXTRACT | |
KR101525877B1 (en) | A composition for preventing wrinkle of skin and anti aging of skin | |
KR102619110B1 (en) | Antioxidant, skin whitening and skin wrinkle improvement composition | |
KR20210003994A (en) | Polysaccharide fraction isolated from Nelumbo nucifera leaf with immune-enhancing activity and method for producing the same | |
KR102154092B1 (en) | A compostion comprising Torreya nucifera seed extract or its fraction having anti-oxidation or anti-inflammation activity | |
KR101986948B1 (en) | COMPOSITION COMPRISING THE EXTRACT OF ACER MONO Max. LEAF FOR ANTIOXIDANT EFFECT | |
KR102100989B1 (en) | Method for producing inner beauty beverage using Chrysanthemum zawadskii and fermeted Rhus verniciflua | |
KR102092729B1 (en) | Pharmaceutical composition for preventing or treating liver damage comprising Curcuma longa extract | |
KR20210047781A (en) | Pharmaceutical composition comprising the extract of prune as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
KR101596006B1 (en) | Composition for Prevention and Treatment of Cardiovascular Diseases | |
KR102488670B1 (en) | Composition for improving memory and learning ability including natural plant extract | |
KR101786180B1 (en) | Composition comprising Spirodela polyrhiza extracts for preventing or treating nonalcoholic fatty liver disease | |
KR102406982B1 (en) | Composition for improving dermatitis comprising extract of Antennaria dioica having antioxidant activity as effective component | |
KR102313083B1 (en) | An anti-oxidative composition comprising an extract of Hydrangea petiolaris or a fraction thereof as an active ingredient | |
KR102590758B1 (en) | Antioxidant or anti-inflammatory composition comprising extract of bilberry containing anthocyanidin components | |
KR20200000174A (en) | Composition for prevention, improvement or treatment of liver fibrosis or cirrhosis including Allium senescens L. Extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GRNT | Written decision to grant | ||
G170 | Re-publication after modification of scope of protection [patent] |